REGENT PACIFIC (00575.HK) strategic partner submits application for new drug to treat premature ejaculation.

REGENT PACIFIC (00575.HK) announced that its commercial strategic partner Jiangsu Wanbang Pharmaceutical submitted a new drug application registration file to the National Medical Products Administration two days ago (17th) and is expected to receive approval within 12 months from the submission date. Jiangsu Wanbang Pharmaceutical is responsible for obtaining and maintaining any and all regulatory approvals required for the import of Senstend in China at its own expense from the National Medical Products Administration. Additionally, importantly, Jiangsu Wanbang Pharmaceutical is fully responsible for the marketing, sales, and distribution of Senstend in China, and will liaise with the manufacturer for the procurement and supply of Senstend to achieve its sales objectives.

AASTOCKSDec 19 09:44

Hong Kong stock announcement to uncover opportunities | SHOUCHENG intends to sell approximately 0.607 billion shares of SHOUGANG RES for about 1.4566 billion Hong Kong dollars.

IDREAMSKY (01119) has reached a cooperation with stc play in the technology and gaming fields. ASCLETIS-B (01672): The candidate drug ASC47 for obesity treatment, when combined with semaglutide, has shown superior weight loss effects compared to semaglutide used alone in preclinical models.

Zhitong FinanceDec 18 23:06

Regent Pacific's Strategic Partners Submits NDA for Premature Ejaculation Drug in China

MT NewswiresDec 18 19:47

REGENT PACIFIC (00575.HK) submitted a new drug application for Senstend to the National Medical Products Administration of China.

Gelonghui reported on December 18 that REGENT PACIFIC (00575.HK) announced that the company's strategic business partner Jiangsu Wanbang Biochemical Pharmaceutical Group Co., Ltd. ("Jiangsu Wanbang Pharmaceutical", a wholly-owned subsidiary of Shanghai FOSUN PHARMA ("FOSUN")) submitted new drug application registration documents to the National Medical Products Administration on December 17, 2024, and approval is expected within 12 months from the submission date.

Gelonghui FinanceDec 18 18:15

REGENT PACIFIC: 2024 Interim Report

HKEXSep 23 16:33 · Announcements

Regent Pacific (00575) announced its interim results, with a net loss of 2.621 million US dollars, a year-on-year decrease of 78.5%.

Regent Pacific (00575) announced its performance for the six months ended June 30, 2024, with a profit of $0.123 million...

Zhitong FinanceAug 28 22:05